Effective against serious diseases, but vaccination This is not enough to contain the new wave of epidemics in the fall. The Institut Pasteur clearly states this in a model published on September 6. The problem is,”Reduced efficacy of vaccines against infectious diseases: we know that it was 80% [avant le variant Delta], We are roughly 60% protection ” today, On France 2, the journalist and doctor Damien Mascret explained himself. To fight against Covid-19 infection, researchers are now relying on a new form of nasal spray vaccine to give patients so-called “mucous” immunity.
What is “mucosal immunity”?
“Mucosal immunity can be associated with the nose, the mouth…” I explained to France Amfo, research director at the National Institute of Health Sciences, who is working on a nasal vaccine against whooping cough at the Institut Pasteur in Lille.
“This is a special type of immunity that is specifically given to the mucous membranes by IgA (immunoglobulin A) antibodies. she grows up..When vs“This is very interesting in the case of a viral infection like Covid because this immunity prevents the virus from entering the cell.”
Why is it a nasal spray vaccine?
Also, to give this mucosal immunity to the nose, researchers are currently trying to develop a nasal spray vaccine. “Local reactions require local immunity. Exit Nathalie Miel Calek.. “These nasal vaccines are therefore antibodies that lower the viral load and have a local response to the nose.” clear, “By preventing the invasion of viruses, it can provide a barrier effect. She specifies. Maybe it’s because we still have to prove it. “
Current vaccines, in this context, develop antibodies and cellular responses, allowing them to fight against the disease, in particular its severe form. However, they do not stop the spread of the virus.
“Current vaccines (Pfizer, Moderna, AstraZeneca) are administered intramuscularly. They lower the viral load and protect against disease, but they do not prevent infection. In other words, they are not completely effective.Natalie Mielkarek, Inserm Research Director
Rémi Salomon, president of the Paris Public Support Medical Commission (AP-HP), posted the same reason on Twitter.
COVID vaccine administered by nasal spray. It is a solution that provides better local immunity (nasal mucosa) than intramuscular vaccines. These confer excellent general immunity via white blood cells and antibodies ⤵️ 1/4
-RemiSalomon (@RemiSalomon) September 9, 2021
… It circulates in the blood, but has weak local immunity and prevents the virus from invading the whole body, but explains why it is less effective against moderate body types and infections. Research is underway at ⤵️
-RemiSalomon (@RemiSalomon) September 9, 2021
“This type of nasal vaccine already exists against the flu in the United States or the United Kingdom. Inactivated virus-based pediatric vaccine that is effective when administered to patients aged 24 months to 18 years. Underline Natalie Mielcarek.. “Another example: the Institut Pasteur in Lille has developed a nasal vaccine against whooping cough. It is in Phase II trials. In the future, we plan to focus more and more on this type of vaccine.
Will this nasal spray vaccine replace the current vaccine?
Warning warning. This is because the research is already at the testing stage. Against the Covid “Currently, there are eight nasal spray vaccines for clinical evaluation. “ Classified by the World Health Organization, it highlights Inserm’s research director. It is therefore difficult to decide before these vaccines are verified by the competent health body.
If so, how can I use them? For Nathalie Mielcarek, « NS Intranasal vaccines can add a new twist to vaccination. “ By acting as a kind of supplement.
“Currently, most French people are protected from severe forms of disease by vaccination, so this nasal vaccine can serve as an additional vaccine to fight viral infections.”Natalie Mielkarek, Inserm Research Director
It is not excluded that this type of vaccine may be effective in countries where vaccination has not yet been developed. “Easy to administer, no injection necessary, very stable at temperature”.. But can they replace the messenger RNA vaccine? “The messenger RNA vaccine has a high efficacy rate, She remembers. It can only be replaced by an intranasal vaccine if this level of efficacy is reached. “
Explain what “mucosal immunity” is, a promising tool for future research on nasal vaccines
Source link Explaining what “mucosal immunity” is, a promising tool for future research on nasal vaccines